The U.S. Food and Drug Administration (FDA) has accepted Enochian BioSciences Pre-IND (Investigational New Drug) request for a potential cure of Hepatitis B (HBV). HBV is a viral infection that affects the liver. The request comes after promising results from a proof-of-concept study using chimeric mice, and written comments are expected during the fall. “The impressive results in the premier animal model gives me great hope that we are on track to develop a commercial product that could potentially cure HBV infection, a disease that causes chronic liver damage in ~350 million people globally and kills nearly 1 million people each year,” stated Dr. Carol Brosgart, UCSF and former Senior Advisor for Science and Policy to the Division of Viral Hepatitis at the CDC and Prevention as well as Clinical Professor of Medicine, Epidemiology and Biostatistics, UCSF.
Read more here.